Evaluation of the Potential Impact of a High-fat Meal on the Pharmacokinetics of CRS3123 in Healthy Adult Participants
A Phase 1, Single-Center, Open-Label, Randomized, Single-Dose, 2-Period, Crossover Study to Evaluate the Potential Impact of High-fat Meal on the Pharmacokinetics of CRS3123 200 mg Capsule in Healthy Adult Participants
Sponsor: Crestone, Inc
A PHASE1 clinical study on Food Effect in Healthy Participants, this trial is completed. The trial is conducted by Crestone, Inc and has accumulated 2 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
2 versions recorded-
Jul 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jun 2025 — Jul 2025 [monthly]
Active Not Recruiting PHASE1
First recorded
May 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Crestone, Inc
- National Institute of Allergy and Infectious Diseases (NIAID)
For direct contact, visit the study record on ClinicalTrials.gov .